TY - JOUR
T1 - Voorzichtig met erytropoëtine bij patiënten met kanker
AU - van der Lelie, J.
PY - 2008/4/19
Y1 - 2008/4/19
N2 - Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.
AB - Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=44949145219&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/18561786
M3 - Comment/Letter to the editor
C2 - 18561786
SN - 0028-2162
VL - 152
SP - 920
EP - 922
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 16
ER -